Compare Star Bulk Carriers Corp (SBLK) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Star Bulk Carriers Corp trades at $28.76 (market cap $3.46B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.2× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.31% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 23 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SBLK | SYRE | |
|---|---|---|
Market Cap | $3.46B | $7.52B |
Volume | 1,078,337 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $32.49 | $108.92 |
52-Week Low | $17.42 | $22.18 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $4.14B | $6.52B |
Dividend Yield | 6.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $29.79, down 0.17% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 23.87% net income margin and has beaten earnings estimates for three consecutive quarters. Recent insider buying activity and a 58.34% analyst buy rating signal confidence, while the stock offers an attractive valuation with P/E of 11.68 and upcoming $0.90 dividend payment.
SBLK presents a compelling value opportunity with strong earnings momentum and shareholder returns, though technical weakness and shipping sector volatility pose near-term risks. The company's 100% free cash flow distribution policy and projected revenue growth to $1.2B in 2026 support the bullish fundamental case, while bearish moving averages suggest potential consolidation before further upside.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
